A new immuno-oncology target - SUMOylation

Trends Cancer. 2023 Aug;9(8):606-608. doi: 10.1016/j.trecan.2023.04.010. Epub 2023 May 11.

Abstract

Immunotherapy has been a paradigm shift in cancer treatment to produce durable responses. Unfortunately, most cancers do not respond to current immunotherapies, and thus, exploring novel mechanisms is crucial. Emerging data now demonstrate that protein modification by the small ubiquitin-like modifiers (SUMO) is a novel target to activate antitumor immunity.

Keywords: NK cells; SUMO; T cells; cancer; dendritic cells; immunotherapy; innate immunity; macrophages.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Neoplasms* / therapy
  • Protein Processing, Post-Translational
  • Small Ubiquitin-Related Modifier Proteins / metabolism
  • Sumoylation*

Substances

  • Small Ubiquitin-Related Modifier Proteins